Forepont Capital Partners is delighted to announce that Ansella Therapeutics, one of its portfolio companies, was named a Challenge Runner-up in the 7th annual M2D2 (Massachusetts Medical Device Development Center) Challenge and was selected to present a poster at the Finalist Award Events on March 28th and April 10th to showcase innovations for women’s health. Ansella was selected out of over 100 companies globally for this highly acclaimed review.
Ansella’s technology incorporates an innovative material characterization technique together with process analysis and novel biochemistry. The result is new, “never-before-possible” treatments for unmet medical needs. Ansella’s innovation is focused on women’s health and was selected by a Review Committee composed of investors and industry experts, including Johnson & Johnson Innovation, Amgen, Boston Scientific amongst others, because of its great merit and potential.
“This recognition is a testament to the strength of Ansella’s team andsolutionfor this large unmet need in women’s health market” said Vishal Jain, a New-York based senior partner at Forepont Capital Partners and a board member of Ansella Therapeutics.
About Ansella Therapeutics. Ansella Therapeutics strives to improve the quality of women’s health by addressing overlooked, unmet medical needs with novel treatment options that are inspired by the intrinsic biology and that provide an innovative solution to actually meet the medical need. Ansella Therapeutics is a specialty pharmaceutical company initially focused on developing novel formulations with gynecological applications.
About Forepont Capital Partners. Headquartered in New York, Forepont Capital Partners, a subsidiary of the Forepont Group, deploys long term and permanent capital to fuel growth of new medicines and technologies that drive better healthcare outcomes.
